The HPV vaccine is approved for anyone ages 9 through 45. Routine vaccination is recommended starting at age 9, with the ideal window being ages 9 to 12, well before any exposure to the virus. Catch-up vaccination is recommended through age 26 for anyone who hasn’t been fully vaccinated, and adults 27 to 45 can still get it after a conversation with their doctor.
The Ideal Age: 9 Through 12
The sweet spot for HPV vaccination is between ages 9 and 12. The original recommendation, set in 2007, targeted ages 11 to 12, but health organizations now encourage starting as early as 9. There are a few reasons for this shift.
First, the vaccine works best when given before any sexual contact, since it prevents new HPV infections but cannot treat existing ones. HPV is commonly acquired soon after a person first has sex, so vaccinating years in advance provides the strongest protection. Antibody levels plateau about 18 to 24 months after the series is completed and then hold steady without significant decline, so there’s no downside to vaccinating a few years earlier than originally recommended.
Second, starting at 9 gives families more flexibility. Instead of bundling the HPV vaccine with several other shots at the 11-year-old checkup, parents can spread things out across annual well-child visits. About 79% of children ages 6 to 11 attend these yearly visits, making it easy to fit in. Starting earlier also sidesteps an awkward barrier: when the vaccine is introduced at 11 or 12, the conversation can feel tied to discussions about sexual activity, which makes some parents hesitant. At age 9, the vaccine is easier to frame as routine cancer prevention.
Two Doses vs. Three Doses
The number of shots you need depends entirely on age at the first dose. Children who start the series between ages 9 and 14 need only two doses, spaced 6 to 12 months apart. Anyone who starts at age 15 or older needs three doses, given over about six months (the second dose at 1 to 2 months, the third at 6 months). People with weakened immune systems also need three doses regardless of age.
This is one of the most practical reasons to vaccinate early. Starting before age 15 means one fewer doctor’s visit and one fewer shot for your child to complete the full series.
Catch-Up Vaccination Through Age 26
If you missed the childhood window, catch-up vaccination is routinely recommended for everyone through age 26. The three-dose schedule applies at this age. While the vaccine is still effective for young adults, its real-world benefit starts to decrease with age simply because more people have already been exposed to HPV through sexual contact. In clinical trials, the vaccine showed the highest protection in participants who were HPV-naïve at the time of vaccination.
Insurance coverage is generally straightforward in this age range. Marketplace plans and most other health plans are required to cover HPV vaccination as a preventive service with no copay or deductible.
Adults 27 to 45: Case by Case
HPV vaccination is not routinely recommended for adults 27 to 45, but it is FDA-approved for this age group and available through what’s called shared clinical decision-making. That means it’s a conversation between you and your doctor about whether vaccination makes sense for your situation.
The key factor is your likelihood of benefiting. Most adults who have been sexually active have already been exposed to at least some HPV strains. The vaccine prevents new infections but does nothing for strains you’ve already encountered. So the math changes depending on your history. Adults with fewer prior sexual partners, or those entering a new sexual relationship, have a higher chance of encountering an HPV type they haven’t been exposed to yet. For them, the vaccine could still offer meaningful protection. Adults with more extensive sexual histories have likely already encountered the most common strains, which reduces the vaccine’s practical benefit.
In a large clinical trial of women ages 24 to 45, the vaccine’s overall efficacy against a combined endpoint of persistent infection and related lesions was about 47% in the general study population. That’s substantially lower than the near-complete protection seen in young adolescents, and it reflects the reality that many participants had prior HPV exposure. Among participants who were confirmed HPV-naïve at enrollment, efficacy was significantly higher.
If you’re in this age range and interested, the vaccine is given as a three-dose series on the same schedule as younger adults. Vaccination should be delayed during pregnancy.
Why Timing Matters So Much
HPV is not like most infections people think about. It’s extraordinarily common, most sexually active people encounter it at some point, and it usually causes no symptoms. The danger is that certain strains can silently cause cell changes over years or decades, eventually leading to cervical, throat, anal, and other cancers. The vaccine targets the highest-risk strains responsible for the vast majority of these cancers.
Because the vaccine is preventive, not therapeutic, every year of delay after potential exposure reduces its value. A 9-year-old who completes the two-dose series gets the full benefit of the vaccine’s protection, locked in before any risk of exposure. A 30-year-old may still benefit, but the window of maximum impact has narrowed. This is why pediatricians increasingly push for vaccination at 9 rather than waiting for the 11-to-12-year visit: not because the immune response is dramatically different, but because it ensures the series is completed well before any possible exposure and reduces the chance of missed appointments derailing the schedule.